Compare AMPL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPL | PCRX |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.0M |
| IPO Year | 2021 | 2010 |
| Metric | AMPL | PCRX |
|---|---|---|
| Price | $13.28 | $23.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $13.42 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 2.2M | 661.2K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.84 | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | $343,214,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $17.43 | $6.78 |
| Revenue Next Year | $14.16 | $8.54 |
| P/E Ratio | ★ N/A | $122.00 |
| Revenue Growth | 14.68 | ★ 26.04 |
| 52 Week Low | $5.51 | $18.80 |
| 52 Week High | $13.33 | $27.66 |
| Indicator | AMPL | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 74.69 | 34.62 |
| Support Level | $6.05 | $22.03 |
| Resistance Level | N/A | $24.34 |
| Average True Range (ATR) | 0.64 | 1.05 |
| MACD | 0.35 | -0.44 |
| Stochastic Oscillator | 88.23 | 4.31 |
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.